UPDATE 1-US appeals court affirms ruling on Risperdal patent
WASHINGTON May 11 (Reuters) - A U.S. appeals court upheld a lower court ruling on Friday that blocked U.S. sales of two copycat versions of the Johnson & Johnson (JNJ.N) antipsychotic drug Risperdal until a J&J patent expires at the end of 2007.
The U.S. Court of Appeals for the Federal Circuit affirmed rulings by a lower court judge in New Jersey that upheld the validity of a key J&J patent on the drug and delayed the effective date of a tentative approval given to Mylan Pharmaceuticals Inc. , a unit of Mylan Laboratories Inc. MYL.N to market its generic Risperdal.
Risperdal generated sales of about $3 billion in 2005.
A lawsuit filed by J&J unit Janssen LP in December 2003 alleged Mylan and India's Dr. Reddy's Laboratories Ltd. (REDY.BO) infringed the Risperdal patent.
Risperdal was approved in 1993 and is marketed as a treatment for schizophrenia, mania associated with manic depression and irritability associated with autism in children and adolescents.
- Tweet this
- Share this
- Digg this
- Moscow fights back after sanctions; battle rages near Ukraine crash site |
- UK's Lloyds says case strengthened for re-starting dividends
- Netanyahu vows to complete Gaza tunnels destruction |
- Insight - European regulators training sights on Google's mobile software
- Russia wants Apple, SAP to cooperate against foreign spying